PON2 Inhibitors encompass compounds that indirectly affect PON2 activity through modulation of lipid metabolism and oxidative stress response. These inhibitors do not target PON2 directly but influence cellular processes and pathways in which PON2 plays a role. In the first category are compounds that modulate lipid metabolism, such as Statins, Fenofibrate, Niacin, and Omega-3 Fatty Acids. Since PON2 is involved in lipid metabolism, these compounds, by altering lipid profiles and related metabolic pathways, can impact PON2's function. For instance, Statins, by inhibiting HMG-CoA reductase, not only lower cholesterol levels but also may influence the metabolic environment in which PON2 operates.
The second category includes antioxidants and compounds that modulate oxidative stress, such as Curcumin, Quercetin, Resveratrol, Sulforaphane, Green Tea Catechins, EGCG, Vitamin E, and Zinc. PON2 has antioxidant properties, and by influencing oxidative stress and cellular antioxidant systems, these compounds could modulate the activity of PON2. For example, Curcumin and Resveratrol, known for their anti-inflammatory and antioxidant effects, might affect the cellular oxidative state and, consequently, the activity of PON2 in mitigating oxidative stress.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Simvastatin | 79902-63-9 | sc-200829 sc-200829A sc-200829B sc-200829C | 50 mg 250 mg 1 g 5 g | $31.00 $89.00 $135.00 $443.00 | 13 | |
Inhibits HMG-CoA reductase, potentially affecting lipid metabolism linked with PON2. | ||||||
Fenofibrate | 49562-28-9 | sc-204751 | 5 g | $41.00 | 9 | |
Modifies lipid profiles, potentially influencing PON2's role in lipid metabolism. | ||||||
Nicotinic Acid | 59-67-6 | sc-205768 sc-205768A | 250 g 500 g | $62.00 $124.00 | 1 | |
Alters lipid metabolism, potentially impacting PON2 function. | ||||||
Zinc | 7440-66-6 | sc-213177 | 100 g | $48.00 | ||
Essential mineral that can affect antioxidant enzyme activities, possibly modulating PON2. | ||||||